share_log

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

單價治療藥和 2 個其他 2 美元以下的股票內部人士正在購買
Benzinga ·  06/03 07:41

The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週五收漲約575點。當內部人士購買或出售股票時,表明他們對公司前景的信心或擔憂。對於有興趣購買低價股的投資者和交易者來說,可以將此視爲其整體投資或交易決策的因素之一。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多,請查看Benzinga內幕交易平台。

Grove Collaborative Holdings

Grove Collaborative Holdings

  • The Trade: Grove Collaborative Holdings, Inc. (NYSE:GROV) President and CEO Jeffrey Michael Yurcisin bought a total of 17,100 shares at an average price of $1.63. To acquire these shares, it cost around $27,951.
  • What's Happening: On May 14, Grove Collaborative posted a narrower-than-expected quarterly loss.
  • What Grove Collaborative Holdings Does: Grove Collaborative Holdings Inc is engaged in providing consumer products.
  • 交易:Grove Collaborative Holdings,Inc.(紐交所:GROV)總裁兼首席執行官Jeffrey Michael Yurcisin以平均價格1.63美元買入了共計17100股。要獲得這些股票,這需要花費約27951美元。
  • 近期動態:5月14日,Grove Collaborative發佈了比預期虧損更小的季度業績。
  • Grove Collaborative Holdings的業務是提供消費品。

Fresh Tracks Therapeutics

Fresh Tracks Therapeutics

  • The Trade: Fresh Tracks Therapeutics, Inc. (OTC:FRTX) 10% owner Exploration Capital, LLC acquired a total of 10,434 shares at an average price of $0.92. To acquire these shares, it cost around $9,580.
  • What's Happening: The company's stock fell around 3% over the past month.
  • 交易:Fresh Tracks Therapeutics,Inc.(場外交易:FRTX)10%股東Exploration Capital,LLC以平均價格0.92美元收購了10434股。獲得這些股票需要花費約9580美元。
  • 近期動態:該公司股票在過去一個月中下跌了約3%。

Monopar Therapeutics

Monopar Therapeutics

  • The Trade: Monopar Therapeutics Inc. (NASDAQ:MNPR) Chief Operating Officer Andrew Cittadine acquired a total of 36,000 shares at an average price of $0.64. The insider spent around $23,051 to buy those shares.
  • What's Happening: On May 24, Monopar said its CFO Kim R. Tsuchimoto will be retiring.
  • What Monopar Therapeutics Does: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.
  • 交易:Monopar Therapeutics Inc.(納斯達克代碼:MNPR)首席運營官Andrew Cittadine以平均價格0.64美元買入了共計36000股。這位內部人士花費約23051美元購買這些股票。
  • 近期動態:5月24日,Monopar表示其首席財務官Kim R. Tsuchimoto將退休。
  • Monopar Therapeutics Inc是一家臨床階段的生物製藥公司,致力於開發用於延長癌症患者壽命或提高生活質量的專有治療方法。

Now Read This: Science Applications International, Autodesk And 3 Stocks To Watch Heading Into Monday

現在讀此:科學應用國際、歐特克和3支週一值得關注的股票

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論